

Donna Johnston-Round 13

Phase I dose finding study for melatonin in pediatric oncology patients with relapsed solid tumors (MEL P1)

Funded in partnership with the Coast-to-Coast Against Cancer Foundation and Childhood Cancer Canada Foundation.

Publications

1. Johnston DL, Zupanec S, Nicksy D, Morgenstern D, Narendran A, Deyell R, Sampson Y, Wu B, Baruchel S. Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors. *Pediatric Blood and Cancer* 2019;66(6):e27676). *We found that melatonin was well tolerated at a dose of 0.3 mg/kg (maximum 20 mg) in the pediatric population. The study provided background for further study of high-dose melatonin in the pediatric oncology population.*

Abstracts and Conference Presentations

1. The study was presented at SIOP in 2018 (Johnston D, Zupanec S, Nicksy D, Morgenstern D, Narendran A, Deyell R, Samson Y, Baruchel S. Phase I dose finding study for melatonin in pediatric oncology patients with relapsed solid tumors. *Pediatric Blood and Cancer* 2018;65:52:S13)

Invited Presentations (including Grand Rounds)

1. Melatonin Update: Presentation for the CHEO Research Institute, April 27th, 2015
2. Melatonin Update at C17 Directors Meeting, Ottawa, May 31, 2017

Knowledge Translation Activities:

1. Dr. Donna Johnston, Chief of Hematology/Oncology at CHEO, discusses her research into the benefits of melatonin and its ability to help cancer patients beat the disease. Adults have successfully used melatonin to help maintain a healthy body weight during chemotherapy and Donna and her research team are now applying this clinical research to children. Published on YouTube Nov 9, 2015 by CHEO Research Intitute.

<https://youtu.be/Sp1S2100-Fg>